Compounds as cannabinoid receptor ligands

1. A compound according to formula (I),

or a pharmaceutically acceptable salt, thereof, wherein

R 1 is alkyl, haloalkyl, G 1 , —(CR x R y ) m -G 1 , or —N(R 1a )(R z );

R 2 is alkyl, haloalkyl, G 2 , —(CR x R y ) m -G 2 , —(CR x R y ) m —OR za , —(CR x R y ) m —N(R za )(R zb )—(CR x R y ) m —C(O)O(R za ), (CR x R y ) m —C(O)R za , —(CR x R y ) m —C(O)N(R za ) (R zb ), —(CR x R y ) m —S(O) 2 O(R za ), —(CR x R y ) m —S(O) 2 R za , —(CR x R y ) m —S(O) 2 N(R za )(R zb ), or —(CR x R y ) m —CN;

G 1 and G 2 , at each occurrence, are each independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; wherein each ring is independently unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, —NO 2 , —CN, halogen, oxo, —OR e , —O—(CR j R k ) n —N(R w ) 2 , —OC(O)R e , —SR e , —S(O)R f , —S(O) 2 R f , —S(O) 2 N(R e )(R g ), —N(R e )(R g ), —N(R g )C(O)R e , —N(R g )S(O) 2 R f , —N(R g )C(O)N(R e )(R g ), —N(R g )S(O) 2 N(R e )(R g ), —C(O)R e , —C(O)O(R e ), —C(O)N(R e )(R g ), haloalkyl, —(CR j R k ) q —CN, —(CR j R k ) q —OR e , —(CR j R k ) q —OC(O)R e , —(CR j R k ) q —SR e , —(CR j R k ) q —S(O)R f , —(CR j R k ) q —S(O) 2 R f , —(CR j R k ) q —N(R e )(R g ), —(CR j R k ) q —N(R g )C(O)R e , —(CR j R k ) q —N(R g )S(O) 2 R f , —(CR j R k ) q —N(R g )C(O)N(R e )(R g ), —(CR j R k ) q —N(R g )S(O) 2 N(R e )(R g ), —(CR j R k ) q —C(O)R e , —(CR j R k ) q —C(O)O(R e ), —(CR j R k ) q —C(O)N(R e )(R g ), —C(R w )═N—OR w , and morpholinyl;

Ring A represents formula (a), (b), (c), or (d)

R 21 , R 22 , R 23 , and R 24 are -alkylene-G 3 wherein G 3 , at each occurrence, is independently a 4-, 5-, 6-, 7-, 8-, or 9-membered monocyclic heterocycle containing zero or one double bond, one or two oxygen, and zero or one nitrogen as ring atoms, and is optionally fused with a monocyclic ring selected from the group consisting of benzo, cycloalkyl, cycloalkenyl, heterocycle and heteroaryl; two non-adjacent atoms of each G 3 are optionally linked by an alkenylene bridge of 2, 3, or 4 carbon atoms, or optionally linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, and each G 3 is independently unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from the group consisting of oxo, alkyl, halogen, —OH, —O(alkyl), —O(haloalkyl), and haloalkyl;

R w , at each occurrence, is independently hydrogen or alkyl;

R 3 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are each independently hydrogen, alkyl, alkenyl, alkynyl, —NO 2 , —CN, halogen, —OR a , —N(R a )(R b ), —C(O)R a , —C(O)O(R a ), haloalkyl, —(CR c R d ) p —OR a , —(CR c R d ) p —N(R a )(R b ), —(CR c R d ) p —C(O)R a , —(CR c R d ) p —C(O)O(R a ), cycloalkyl, cycloalkenyl, or heterocycle;

R 4 and R 5 , are each independently hydrogen, alkyl, alkenyl, alkynyl, —NO 2 , —CN, halogen, —OR a , —N(R a )(R b ), —C(O)R a , —C(O)O(R a ), haloalkyl, —(CR c R d ) p —OR a , —(CR c R d ) p —N(R a )(R b ), —(CR c R d ) p —C(O)R a , —(CR c R d ) p —C(O)O(R a ), cycloalkyl, cycloalkenyl, or heterocycle;

R a , R b , R 1a , R za , and R zb , at each occurrence, are each independently hydrogen, alkyl, or haloalkyl;

R x , at each occurrence, is independently hydrogen, halogen, alkyl, or haloalkyl;

R y , R c , and R d , at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl;

X 1 and X 2 are independently O, S, or N(R 10 ) wherein R 10 is alkyl, alkoxyalkyl, haloalkoxyalkyl, or haloalkyl;

the cycloalkyl, cycloalkenyl, and heterocycle, as represented by R 3 , R 4 , R 5 , R 6 , R 8 , and R 9 are each independently unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, —NO 2 , —CN, halogen, oxo, —OR e , —OC(O)R e , —SR e , —S(O)R f , —S(O) 2 R f , —S(O) 2 N(R e ) (R g ), —N(R e ) (R g ), —N(R g )C(O)R e , —N(R g )S(O) 2 R f , —N(R g )C(O)N(R e )(R g ), —N(R g )S(O) 2 N(R e ) (R g ), —C(O)R e , —C(O)R e , —C(O)O(R e ), —C(O)N(R e )(R g ), haloalkyl, —(CR i R k ) q —CN, —(CR j R k ) q —OR e , —(CR i R k ) q —OC(O)R e , —(CR j R k ) q —SR e , —(CR j R k ) q —S(O)R f , —(CR j R k ) q —S(O) 2 R f —(CR j R k ) q —N(R e )(R g ), —(CR j R k ) q —N(R e )C(O)R e , —(CR j R k ) q —N(R g )S(O) 2 R f , —(CR j R k ) q —N(R g ) C(O)N(R e )(R g ), —(CR j R k ) q —N(R g )S(O) 2 N(R e )(R g ), —(CR j R k ) q —C(O)R e , —(CR j R k ) q —C(O)O(R e ) and —(CR j R k ) q —C(O)N(R e )(R g );

R e and R g , at each occurrence, are each independently hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, haloalkoxyalkyl, or haloalkyl; wherein the cycloalkyl, and the heterocycle moieties, by itself or as part of the substituents of R e and R g , are each independently unsubstituted or substituted with 1, 2, 3, 4, 5 or 6 substituents selected from the group consisting of alkyl, halogen, and haloalkyl;

R f , at each occurrence, is independently alkyl or haloalkyl;

R j and R k , at each occurrence, are each independently hydrogen, halogen, alkyl, or haloalkyl;

m, p, and q, at each occurrence, are each independently 1, 2, 3, or 4; and

n is 2, 3or 4.

2. The compound of claim 1 having formula (I), or a pharmaceutically acceptable salt thereof, wherein R 21 , R 22 , R 23 , and R 24 are -alkylene-G 3 ,

G 3 , at each occurrence, is independently a 4-, 5-, or 6-membered monocyclic heterocycle containing zero or one double bond, one or two oxygen, and zero or one nitrogen as ring atoms, and each G 3 is independently unsubstituted or substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from the group consisting of oxo, alkyl, halogen, —OH, —O(alkyl), —O(haloalkyl), and haloalkyl.

3. The compound of claim 2 having formula (I), or a pharmaceutically acceptable salt thereof, wherein G 3 , at each occurrence, is independently oxetanyl, oxazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxalanyl, or 1,4-dioxanyl, each of which is independently unsubstituted or substituted.

4. The compound of claim 2 having formula (I), or a pharmaceutically acceptable salt thereof wherein R 21 , R 22 , R 23 , and R 24 are each independently tetrahydrofuranylmethyl, tetrahydropyranylmethyl, or oxazolidinylmethyl, and the tetrahydrofuranyl, oxazolidinyl, and the tetrahydropyranyl moieties are each independently unsubstituted or substituted.

5. The compound of claim 2 having formula (I), or a pharmaceutically acceptable salt thereof, wherein ring A is formula (a).

6. The compound of claim 5 having formula (I), or a pharmaceutically acceptable salt thereof, wherein X 1 is S.

7. The compound of claim 6 having formula (I), or a pharmaceutically acceptable salt thereof, wherein R 1 is phenyl or naphthyl, each of which is optionally substituted.

8. The compound of claim 6 having formula (I), or a pharmaceutically acceptable salt thereof, wherein R 1 is —N(R 1a )(R z ).

9. The compound of claim 2 having formula (I), or a pharmaceutically acceptable salt thereof, wherein ring A is formula (b).

10. The compound of claim 9 having formula (I), or a pharmaceutically acceptable salt thereof, wherein X 2 is O.

11. The compound of claim 9 having formula (I), or a pharmaceutically acceptable salt thereof, wherein X 2 is N(R 10 ) and R 10 is alkyl.

12. The compound of claim 9 having formula (I), or a pharmaceutically acceptable salt thereof, wherein R 1 is phenyl or naphthyl, each of which is optionally substituted.

13. The compound of claim 2 having formula (I), or a pharmaceutically acceptable salt thereof, wherein ring A is formula (c).

14. The compound of claim 13 having formula (I), or a pharmaceutically acceptable salt thereof, wherein R 1 is phenyl or naphthyl, each of which is optionally substituted.

15. The compound of claim 2 having formula (I), or a pharmaceutically acceptable salt thereof, wherein ring A is formula (d).

16. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of

5-chloro-2-methoxy-N-[(2Z)-3-[(2R)-tetrahydrofuran-2-ylmethyl]-5-[1-(trifluoromethyl)cyclopropyl]-1,3,4-thiadiazol-2(3H)-ylidene]benzamide;

5-chloro-N-[(2Z)-5-cyclopropyl-3-(tetrahydrofuran-2-ylmethyl)-1,3,4-thiadiazol-2(3H)-ylidene]-2-methoxybenzamide;

N-[(2Z)-5-cyclopropyl-3-(tetrahydrofuran-2-ylmethyl)-1,3,4-thiadiazol-2(3H)-ylidene]-2-ethoxybenzamide;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;

5-chloro-2-methoxy-N-[(2Z)-5-(1-methylcyclopropyl)-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]benzamide;

5-chloro-N-[(2Z)-5-(1,1-dimethylprop-2-ynyl)-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-2-methoxybenzamide;

5-chloro-2-methoxy-N-[(2Z)-5-(2,2,3,3-tetrafluoro-1-methylcyclobutyl)-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]benzamide;

5-chloro-2-methoxy-N-[(2Z)-3-[(2R)-tetrahydrofuran-2-ylmethyl]-5-[1-(trifluoromethyl)cyclobutyl]-1,3,4-thiadiazol-2(3H)-ylidene]benzamide;

5-chloro-2-methoxy-N-[(2Z)-3-[(2R)-tetrahydrofuran-2-ylmethyl]-5-(2,2,2-trifluoro-1,1-dimethylethyl)-1,3,4-thiadiazol-2(3H)-ylidene]benzamide;

5-chloro-2-methoxy-N-[(2E)-5-methyl-1-(tetrahydrofuran-2-ylmethyl)pyridin-2(1H)-ylidene]benzamide;

N-[5-tert-butyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]isoxazol-3(2H)-ylidene]-5-chloro-2-methoxybenzamide;

N-{5-tert-butyl-1-methyl-2-[(2S)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-5-chloro-2-methoxybenzamide; and

N-[5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-oxazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide.

17. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carrier.

18. A method for treating pain in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof.

19. A method for treating an inflammatory disorder in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof.

20. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-ethoxy-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-[(3,3-difluorocyclobutyl)methoxy]-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(3-methoxy-3-methylbutoxy)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(2-fluoroethoxy)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(2-methoxyethoxy)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-hydroxy-5-(trifluoromethyl)benzamide;

2-tert-butoxy-N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-[2-(dimethylamino) ethoxy]-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(dimethylamino)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-{[(2S)-2-methoxypropyl]oxy}-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(3-ethoxypropoxy)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(3-methoxypropoxy)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(2-ethoxyethoxy)-5-(trifluoromethyl)benzamide;

2-methoxy-N-{(3E)-1-methyl-5-(1-methylcyclopropyl)-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-[(2-methoxyethyl)amino]-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(2,2-difluoroethoxy)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-[(3R)-tetrahydrofuran-3-yloxy]-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-[(3S)-tetrahydrofuran-3-yloxy]-5-(trifluoromethyl)benzamide;

(E)-N-(5-tert-butyl-2-(((2R,3R)-3-fluorotetrahydrofuran-2-yl)methyl)-1-methyl-1H-pyrazol-3(2H)-ylidene)-2-methoxy-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-[(2-fluoroethyl)amino]-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(2-fluoropropoxy)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-{[(2R)-2-fluoropropyl]oxy}-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(2-fluoro-1-methylethoxy)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(3-fluoro-3-methylbutoxy)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-fluoro-3-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-methoxy-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-5-cyano-2-methoxybenz amide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-chloro-5-fluorobenz amide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2,3,5-trifluorobenzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-3-chloro-2-fluoro-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-3-chloro-2-methoxy-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-chloro-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-3,5-difluoro-2-methoxybenzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-3-chloro-2-(2-methoxyethoxy)-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-3-chloro-2-(2-fluoroethoxy)-5-(trifluoromethyl)benzamide;

5-bromo-N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(2-methoxyethoxy)benzamide;

5-bromo-N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(2-fluoroethoxy)benzamide;

5-bromo-N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2,3-dihydro-1-benzofuran-7-carboxamide;

N-[(2E)-4-tert-butyl-1-[(2R)-tetrahydrofuran-2-ylmethyl]pyridin-2(1H)-ylidene]-5-chloro-2-methoxybenzamide;

N-[(2E)-4-tert-butyl-1-[(2R)-tetrahydrofuran-2-ylmethyl]pyridin-2(1H)-ylidene]-2-methoxy-5-(trifluoromethyl)benzamide;

N-[(3E)-5-tert-butyl-1-methyl-2-(tetrahydro-2H-pyran-2-ylmethyl)-1,2-dihydro-3H-pyrazol-3-ylidene]-2-methoxy-5-(trifluoromethyl)benzamide;

N-((3E)-5-tert-butyl-1-methyl-2-{[(5R)-5-methyltetrahydrofuran-2-yl]methyl}-1,2-dihydro-3H-pyrazol-3-ylidene)-2-methoxy-5-(trifluoromethyl)benzamide;

N-((3E)-5-tert-butyl-1-methyl-2-{[(5S)-5-methyltetrahydrofuran-2-yl]methyl}-1,2-dihydro-3H-pyrazol-3-ylidene)-2-methoxy-5-(trifluoromethyl)benzamide;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-oxazol-2(3H)-ylidene]-2-methoxy-5-(trifluoromethyl)benzamide;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-(4-methylcyclohexyl)urea;

N-(1-adamantylmethyl)-N′-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]urea;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-{[(1S,2R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]methyl}urea;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-[1-(hydroxymethyl)-3-methylbutyl]urea;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-(1,2-dimethylpropyl)urea;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-(1-ethylpropyl)urea;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-1,2,3,4-tetrahydronaphthalen-1-ylurea;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-[(1S)-1-cyclohexylethyl]urea;

N-(tert-butyl)-N′-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]urea;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]urea;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-cycloheptylurea;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-(2-ethylhexyl) urea;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-(1-methyl-3-phenylpropyl)urea;

N 2 -({[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]amino}carbonyl)-L-isoleucinamide;

N 2 -({[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]amino}carbonyl)-N′,3-dimethyl-L-valinamide;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-neopentylurea;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-N′-[(1S)-1-(hydroxymethyl)-2-methylpropyl]urea;

N-[(3E)-5-tert-butyl-1-methyl-2-(tetrahydrofuran-3-ylmethyl)-1,2-dihydro-3H-pyrazol-3-ylidene]-2-methoxy-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-methyl-5-(trifluoromethyl)benzamide;

N-{(3E)-4-bromo-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-methyl-5-(trifluoromethyl)benzamide;

2-bromo-N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(3-methoxypropyl)-5-(trifluoromethyl)benzamide;

N-[(2Z)-5-tert-butyl-3-{[(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl}-1,3,4-thiadiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide;

2-(2-amino-2-methylpropoxy)-N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-5-(trifluoromethyl)benzamide;

2-(azetidin-3-yloxy)-N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-oxazol-2(3H)-ylidene]-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-3-fluoro-5-(trifluoromethyl)benzamide;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4-thiadiazol-2(3H)-ylidene]-2-{[(3S)-1-methylpyrrolidin-3-yl]oxy}-5-(trifluoromethyl)benzamide;

N-[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-oxazol-2(3H)-ylidene]-2-{[(3S)-1-methylpyrrolidin-3-yl]oxy}-5-(trifluoromethyl)benzamide;

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-[(1E)-prop-1-enyl]-5-(trifluoromethyl)benzamide; and

N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-2-(3-hydroxy-3-methylbutyl)-5-(trifluoromethyl)benzamide.

21. A method for treating an immune disorder in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the immune disorder is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, systemic lupus, myasthenia gravis, type 1 diabetes, irritable bowel syndrome, psoriasis, psoriatic arthritis, hepatitis, tissue rejection in organ transplants, gluten-sensitive enteropathy (Celiac disease), asthma, chronic obstructive pulmonary disease, emphysema, bronchitis, acute respiratory distress syndrome, allergies, allergic rhinitis, dermatitis, and Sjogren's syndrome.

22. A method for treating Alzheimer's disease in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof.

23. A method for treating a respiratory disorder in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the respiratory disorder is selected from the group consisting of pulmonary inflammation, chronic cough, asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis.

24. A method for treating a cardiovascular disorder in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the cardiovascular disorder is selected from the group consisting of atherosclerosis, ischemia, reperfusion, and myocardial infarction.